A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) in Subjects With Type 2 Diabetes Mellitus Using Two Different Titration Algorithms

Study identification

NCT ID

NCT02298192

Recruitment status

Completed

Study type

Interventional

Phase

Phase 3

Lead sponsor

Novo Nordisk A/S

Industry

Enrollment

420 participants

Conditions and interventions

Eligibility (public fields only)

Age range

18 Years and older

Sex

All

Healthy volunteers

Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date

Nov 20, 2014

Primary completion

Dec 22, 2015

Completion

Dec 22, 2015

Last update posted

May 22, 2017

2014 – 2015

United States locations

U.S. sites

40

U.S. states

21

U.S. cities

37

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 44 non-U.S. sites.

Recently updated Diabetes trials

Other public records listing Diabetes. Sorted by last update posted; newest first. Not a recommendation.

• NCT07784127: Whole Gut Motility Abnormalities Following GLP-1 Receptor Agonist (GLP-1RA) Initiation Not yet recruiting
• NCT02262806: Compassionate Use of Metreleptin in Previously Treated People With Partial Lipodystrophy Active, not recruiting
• NCT07748858: Improving Patient-Centered Care for Underserved Older African American Patients With Cardiovascular Comorbidities Recruiting
• NCT05561595: Transdiagnostic Intervention to Reduce Internalized Health-Related Stigma Recruiting
• NCT05912647: Enhancing Diabetes Management Approaches for Patients With Uncontrolled Diabetes Recruiting
• NCT07676188: Leveraging Interventions for Needs and Knowledge in Diabetes (LINKD) Not yet recruiting

All Diabetes trials →